Baruchel A, Cayuela J M, MacIntyre E, Berger R, Sigaux F
Laboratory of Molecular Haematology, St Louis Hospital, Paris, France.
Br J Haematol. 1995 May;90(1):85-93. doi: 10.1111/j.1365-2141.1995.tb03384.x.
Junctional sequences of immunoglobulin (Ig)/T-cell receptor (TCR) gene rearrangements are used as patient-specific PCR targets for the detection of minimal residual disease (MRD) in acute lymphoblastic leukaemias (ALLs). Clonal evolution of gene rearrangements is a major pitfall of this strategy. Using high-resolution PCR-based analyses (including denaturing gel electrophoresis and single-stranded conformation polymorphism (SSCP)) we have compared Ig/TCR gene rearrangements at presentation and relapse in a series of ALLs. These methods allow an unambigous comparison of rearrangements taking into account junctional size and nucleotide sequence information and allow a precise assessment of the clonal evolution. V gamma-J gamma and V delta 1-J delta 1 rearrangements were analysed in 12 T-ALLs. VH-JH, V gamma-J gamma, V delta 2-D delta 3 and, in selected cases, DH-JH rearrangements were studied in 14 B-lineage ALLs. Clonal evolution, regarding major rearrangements, occurs for at least one of these loci in 2/12 T-ALLs and in 5/14 B-lineage ALLs. Clonal evolution is more marked for minor rearrangements than for major ones. As shown using SSCP analysis, rearrangements observed at relapse are sometimes found in minor clones at presentation which are therefore selected in vivo by a proliferative advantage. These data, as well as those from the available literature, suggest the use of at least two patient-specific probes to detect MRD in ALLs. A general strategy including selected Ig/TCR rearrangements and chromosomal abnormalities as PCR targets is proposed.
免疫球蛋白(Ig)/T细胞受体(TCR)基因重排的连接序列被用作患者特异性PCR靶点,用于检测急性淋巴细胞白血病(ALL)中的微小残留病(MRD)。基因重排的克隆进化是该策略的一个主要缺陷。我们使用基于PCR的高分辨率分析方法(包括变性凝胶电泳和单链构象多态性(SSCP)),比较了一系列ALL患者初诊和复发时的Ig/TCR基因重排情况。这些方法能够在考虑连接片段大小和核苷酸序列信息的基础上,对重排进行明确的比较,并能精确评估克隆进化情况。对12例T-ALL患者的Vγ-Jγ和Vδ1-Jδ1重排进行了分析。对14例B系ALL患者的VH-JH、Vγ-Jγ、Vδ2-Dδ3重排以及在选定病例中的DH-JH重排进行了研究。在2/12例T-ALL患者和5/14例B系ALL患者中,至少有一个这些位点发生了主要重排的克隆进化。次要重排的克隆进化比主要重排更为明显。如SSCP分析所示,复发时观察到的重排有时在初诊时的小克隆中就已存在,因此这些小克隆在体内因增殖优势而被选择。这些数据以及现有文献的数据表明,在ALL中检测MRD至少应使用两种患者特异性探针。我们提出了一种包括选定的Ig/TCR重排和染色体异常作为PCR靶点的总体策略。